ENLV, IL0011319527

Enlivex moves reverse split vote. Nasdaq sets USD 1.00 floor for Enlivex stock

Published on 10/18/2026 at 13:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 2 filing set a 1-for-13 to 1-for-16 vote for October 16. A USD 1.00 Nasdaq floor still governs Enlivex stock through October 21.

Governance and listing pressure

On October 2, 2026, Enlivex amended its meeting materials for a 1-for-13 to 1-for-16 reverse split.
First-half 2026 net income reached USD 1.95 billion after paper gains.
Nasdaq could issue a delisting determination after 30 sub-USD 1.00 trading days through October 21, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex Therapeutics Ltd. (ISIN IL0011319527) amended its reverse-split meeting materials on October 2, 2026, setting a first split range of 1-for-13 to 1-for-16. The filing also tied the proposal to Nasdaq's USD 1.00 minimum bid requirement, with a potential delisting determination after 30 consecutive sub-USD 1.00 trading days through October 21, 2026, according to StockTitan.

Nasdaq compliance drives the proposal

The October 2 amendment moved Enlivex's extraordinary general meeting to October 16, 2026, and gave the board authority to choose the final ratio within the 1-for-13 to 1-for-16 range. It also sought authorization for additional reverse splits with an aggregate ratio from 1-for-2 to 1-for-1,000 during the following 12 months, subject to shareholder approval.

The filing said Enlivex shares had closed below the USD 1.00 minimum bid price on each trading day from September 10, 2026, through the filing date. The proposal would reduce the share count while leaving ownership percentages and voting rights unchanged, apart from the treatment of fractional shares.

Three dated steps shape the case

On September 22, 2026, Enlivex terminated a previously announced financing payable in RAIN tokens, according to the company's investor-relations page. On September 25, 2026, the company reported USD 1.95 billion of net income for the first half of 2026, driven largely by paper gains, according to StockTitan. On October 2, 2026, the amended filing set the October 16 meeting and the 1-for-13 to 1-for-16 proposal.

What dates matter for investors?

The October 21, 2026 threshold is the key compliance date identified in the filing. The next scheduled earnings date is November 13, 2026, according to EarningsToday.

Listing status remains the market issue

Enlivex is a clinical-stage biotechnology company developing Allocetra while also managing a treasury strategy linked to the Rain prediction-markets protocol. The Nasdaq listing pressure makes the proposed share consolidation more than a capital-structure exercise because the filing links it directly to continued exchange compliance.

The last available euro indication from Lang & Schwarz was EUR 0.18 on October 16, 2026 at 11:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Enlivex stock.